Cart (0 Items)
Your cart is currently empty.
View ProductsBrand | ProteoGenix |
---|---|
Product type | Elisa assay kits |
Size | 96T |
Product name | Depatuxizumab ELISA Kit |
---|---|
Delivery condition | Blue ice (+4°) |
Storage condition | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
Brand | ProteoGenix |
Size | 96T |
Reference | KPTX120 |
Note | For research use only. |
Sample type | Plasma, Serum |
Immunogen | Depatuxizumab |
Depatuxizumab ELISA Kit is a highly sensitive and specific diagnostic tool used for the detection and quantification of Depatuxizumab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This kit has been developed for use in various research and clinical applications, providing accurate and reliable results.
Depatuxizumab is a recombinant humanized monoclonal antibody, also known as ABT-414, that specifically binds to the extracellular domain of EGFR. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 25 kDa. The antibody has a high affinity for EGFR, with a dissociation constant (Kd) of 0.4 nM, making it a potent therapeutic agent.
EGFR is a transmembrane receptor that plays a crucial role in cell proliferation, differentiation, and survival. Overexpression of EGFR has been observed in various cancers, making it a promising therapeutic target. Depatuxizumab binds to EGFR on the cell surface, blocking its activation and downstream signaling pathways. This results in the inhibition of cell growth and induction of apoptosis, leading to the suppression of tumor growth.
The Depatuxizumab ELISA Kit has been widely used in both research and clinical settings for the detection and quantification of Depatuxizumab in various biological samples. It is a valuable tool for monitoring the pharmacokinetics and pharmacodynamics of Depatuxizumab in patients receiving treatment. The kit can also be used to assess the levels of Depatuxizumab in preclinical studies, aiding in the development of effective dosing regimens.
Depatuxizumab ELISA Kit has been particularly useful in the diagnosis of EGFR-positive cancers, such as glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). These cancers are known to have a high expression of EGFR, making them suitable targets for Depatuxizumab therapy. The kit can accurately measure the levels of Depatuxizumab in patient samples, providing valuable information for treatment planning and monitoring.
As Depatuxizumab is a targeted therapy, its efficacy is dependent on the expression levels of EGFR in the tumor. The Depatuxizumab ELISA Kit can be used to assess the levels of EGFR in patient samples, which can help predict the response to Depatuxizumab treatment. This information can aid in selecting the most appropriate treatment for individual patients, improving treatment outcomes.
Apart from its clinical use, the Depatuxizumab ELISA Kit is also widely used in research studies to investigate the role of EGFR in various cancers and to evaluate the efficacy of Depatuxizumab in preclinical models. The kit provides a sensitive and reliable method for quantifying Depatuxizumab levels in different biological samples, such as serum, plasma, and tissue lysates.
In conclusion, Depatuxizumab ELISA Kit is a valuable tool for the detection and quantification of Depatuxizumab in various biological samples. Its high sensitivity and specificity make it a reliable diagnostic and research tool for studying the role of EGFR in cancer and assessing the response to Depatuxizumab therapy. With its multiple applications and user-friendly format, this kit has become an essential tool for researchers and clinicians in the field of cancer therapeutics.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.